Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.33 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 2/20 | 0.30 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17827390 | 1.00 | DRD2 (0.34) | DRD2DRD3KDM2BKAT2BPARP1 | |
| SCHEMBL24091383 | 0.88 | HRH3 (0.37) | HRH3 | |
| SCHEMBL20711726 | 0.88 | HRH3 (0.37) | HRH3 | |
| SCHEMBL147039 | 0.88 | HRH3 (0.37) | HRH3 | |
| SCHEMBL21217149 | 0.85 | — | — | |
| SCHEMBL21191907 | 0.84 | HRH3 (0.40) | HRH3 | |
| SCHEMBL19865706 | 0.82 | HRH3 (0.31) | HRH3 | |
| SCHEMBL21476048 | 0.82 | KDM2B (0.37) | DRD2DRD3KDM2BKAT2BPARP1 | |
| SCHEMBL749969 | 0.82 | KDM2B (0.37) | DRD2DRD3KDM2BKAT2BPARP1 | |
| SCHEMBL12026428 | 0.82 | KDM2B (0.37) | DRD2DRD3KDM2BKAT2BPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10392368-B2 | Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-08-27 | — | — | US | disclosed |
| US-20190040043-A1 | PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190040043-A1 | PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS | JAK3, JAK1, JAK2 | DRD2 4030/4885DRD3 2203/4885KDM2B 2164/4885 |
| US-10392368-B2 | Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors | JAK3, JAK1, JAK2 | DRD2 4030/4885DRD3 2203/4885KDM2B 2164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.